Enovix Form 4: Director converts 6,299 warrants; RSUs total 22,543

Rhea-AI Filing Summary

Pegah Ebrahimi, a director of Enovix Corporation (ENVX), exercised publicly traded warrants on 08/29/2025 to acquire 6,299 shares of common stock at an exercise price of $8.75 per share. The warrants were originally distributed on July 21, 2025 and were subject to an acceleration provision that caused the expiration to accelerate to August 29, 2025; the warrants ceased to be exercisable prior to 5:00 p.m. New York City time on that date.

After the reported transaction, Ebrahimi beneficially owned 72,939 shares, which includes 22,543 shares issuable upon settlement of restricted stock units. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.

Positive

• Director purchased equity: Exercise of 6,299 warrants at $8.75 increased the reporting person's direct common stock holdings, aligning interests with shareholders.
• Material ownership disclosure: Post-transaction beneficial ownership of 72,939 shares is clearly reported, including 22,543 RSU interest which clarifies compensation-related holdings.
• Transparent execution: Acceleration and cessation of warrant exercisability are explicitly disclosed, providing clarity on the timing and contractual terms.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director exercised warrants and increased stock ownership by 6,299 shares at $8.75, leaving total beneficial ownership of 72,939 shares.

The filing documents a routine insider exercise of publicly traded warrants distributed July 21, 2025. The exercise price and number of shares are explicitly stated: 6,299 warrants exercised at $8.75 per share resulting in 6,299 common shares issued. Post-transaction beneficial ownership is 72,939 shares, which includes 22,543 RSU-settled shares. The acceleration of the warrant expiration to August 29, 2025 is noted and is a contractual event rather than a new corporate action. This disclosure provides clear, specific metrics investors can use to update insider ownership figures.

Corporate Governance Expert

TL;DR: The Form 4 records a disclosed, authorized exercise and provides transparency on executive compensation and ownership.

The report shows the reporting person acted under existing warrant and RSU agreements: warrants distributed July 21, 2025 with exercise rights and RSUs representing 22,543 shares. The form is properly executed by an attorney-in-fact and discloses the acceleration of the warrants' expiration per the Warrant Agreement. The filing is a standard Section 16 disclosure that updates beneficial ownership without indicating any undisclosed governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ebrahimi Pegah

(Last) (First) (Middle)

C/O ENOVIX CORPORATION

3501 W. WARREN AVENUE

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enovix Corp [ ENVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		X		6,299(1)	A	$8.75	72,939(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$8.75	08/29/2025		X			6,299(1)	07/21/2025	08/29/2025(3)	Common Stock, par value $0.0001	6,299	$0	0	D

Explanation of Responses:

1. Reflects shares issued upon the exercise of publicly-traded warrants (the "Warrants") by the Reporting Person. The Warrants were distributed by the Issuer on July 21, 2025, and each Warrant entitles the holder to purchase one share of common stock at an exercise price of $8.75 per share in accordance with the Warrant Agreement dated July 21, 2025 between the Issuer and Computershare Trust Company N.A., as warrant agent (the "Warrant Agreement").

2. Includes 22,543 shares issuable upon the settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

3. In accordance with the Warrant Agreement, the original expiration date ceased to be exercisable at 5:00 p.m. New York City time on October 1, 2026 (the Expiration Date), subject to automatic acceleration upon satisfaction of the early expiration price condition. On August 28, 2025, the early expiration price condition was met and the expiration date for the warrants was accelerated to be on August 29, 2025. The Warrants was ceased to be exercisable prior to 5:00pm New York City time on August 29, 2025.

Remarks:

	/s/ Arthi Chakravarthy, Attorney-in-Fact for Pegah Ebrahimi	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pegah Ebrahimi report on Form 4 for Enovix (ENVX)?

The Form 4 reports that Pegah Ebrahimi exercised 6,299 publicly traded warrants on 08/29/2025 at an exercise price of $8.75 per share and thereby acquired 6,299 common shares.

How many shares does the reporting person beneficially own after the transaction?

After the transaction the reporting person beneficially owned 72,939 shares, which includes 22,543 shares issuable upon settlement of RSUs.

Why did the warrants cease to be exercisable on August 29, 2025?

Per the Warrant Agreement the warrants had an original expiration and an early expiration price condition; that condition was met on 08/28/2025 and the expiration was accelerated to 08/29/2025, after which the warrants ceased to be exercisable prior to 5:00 p.m. New York City time.

What was the original distribution date of the warrants?

The warrants were distributed by the issuer on July 21, 2025 under a Warrant Agreement with Computershare Trust Company N.A. as warrant agent.

Who signed the Form 4?

The Form 4 was signed by /s/ Arthi Chakravarthy, Attorney-in-Fact for Pegah Ebrahimi with a signature date of 09/02/2025.